Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate
Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.
You may also be interested in...
In an interview at the recent BioPharm America conference, Shah explains the role that BioMotiv, a self-described accelerator, plays in advancing academic research into private-sector biopharma companies.
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Mnemo Therapeutics’ promise in chimeric antigen receptor (CAR) T-cell therapy technologies allowed it to raise €75m in a series A financing round and the French biotech’s CEO tells Scrip he aims to raise yet more money in coming months to fund its development plans.